Search

Displaying results 3651 - 3660 of 7897 in total
  1. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

  2. Drug

    Ammonium trichlorotellurate

    go.drugbank.com/drugs/DB17740
    Investigational

    Ammonium trichlorotellurate is an investigational compound with anti-tumour [A259147] and anti-inflammatory properties.[A259152]

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  4. Drug

    SB-509

    go.drugbank.com/drugs/DB05579
    Investigational

    SB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.

  5. Drug

    Biopterin

    go.drugbank.com/drugs/DB03886
    Experimental

    A natural product that has been considered as a growth factor for some insects. [PubChem]

  6. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  7. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

    Synonyms: ABX 1100, ABX-1100
  8. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Unlike [DB01132], which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist. … It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells.

  9. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  10. Drug

    Ethionamide

    go.drugbank.com/drugs/DB00609
    ApprovedInvestigationalWithdrawn

    A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)